Dendreon went up for the following reason. "It reported better than expected sales of its prostate cancer therapy Provenge. Dendreon attributed the boost to improved insurance reimbursement for the product, noting that the average reimbursement period for prescribing physicians had dropped to less than 30 days."
This was all due to the "Q" reimbursement code a number of months ago to DNDN. HGSI will be issued a "Q" reimbursement code this month. See the similarities!
HGSI will also see a boost in sales once the "Q" code reimbursements kick in. Once that happens a HGSI reports improved sales just like DNDN, you will see HGSI go up at least $3 a share if not more.
So to answer your question HGSI's gains today are directly related to DNDN because we will have the same reaction once the expanded reimbursement code starts being submitted for payment.